All In Biotech

Drug Trial Radar · NCT07203365

RSV Immunogenicity Study in the Elderly (RISE)

Immunogenicity After a Prime Dose and Revaccination With Adjuvanted RSVPreF3 Vaccine in the Most Elderly and Frail Population - an Open-labeled Phase IIIb-trial

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

75

Actual

Start

Aug 25, 2025

Primary completion

May 31, 2027

Study completion May 31, 2029

Sponsor

Lead sponsor
Karin Karin LoréAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Karolinska Institutet
First posted
Oct 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Respiratory syncytial virus (RSV) is a common cause of respiratory tract infections leading to hospitalizations in infants and in elderly. Arexvy is an approved vaccine for the prevention of RSV infection, however, data on its efficacy in individuals aged 80 years and older remain limited. This study aims to evaluate potential differences in immune responses to Arexvy vaccination between adults aged ≥80 years and those aged 60-65 years.

Conditions

  • RSV Immunisation

Interventions

  • This study examines immune response differences Arexvy between individuals aged 80+ and adults aged 60-65Biological

    The RSV vaccine (Arexvy) has demonstrated efficacy against LRTD over three RSV seasons in individuals aged 60 and older, with an acceptable safety and reactogenicity profile. However, data on vaccine responses in individuals aged 80 and older, including frail individuals, remains limited. This population is particularly affected by severe RSV infections, highlighting the need for further investigation to address these gaps.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary endpoint:Time frame: Day 31
  2. Primary objectiveTime frame: Day 31

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Familjeläkarna SÄBO

    Saltsjöbaden, Sweden

  • Akademiskt specialistcentrum Studieenheten

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.